Download full-text PDF

Source

Publication Analysis

Top Keywords

[meningococcic sepsis
4
sepsis statistical
4
statistical study]
4
[meningococcic
1
statistical
1
study]
1

Similar Publications

Microbiology reference laboratories perform a crucial role within public health systems. This role was especially evident during the COVID-19 pandemic. In this Viewpoint, we emphasise the importance of microbiology reference laboratories and highlight the types of digital data and expertise they provide, which benefit national and international public health.

View Article and Find Full Text PDF

Infections in sickle cell disease.

Haematologica

November 2024

Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK; Red Cell Haematology, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London.

Sickle cell disease (SCD) is one of the commonest severe inherited disorders in the world. Infection accounts for a significant amount of the morbidity and mortality, particularly in sub- Saharan Africa, but is relatively poorly studied and characterized. Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself.

View Article and Find Full Text PDF

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.

Neurology

November 2024

From the Department of Neurology (M.R., K.F., S.G.M., O.A.), Medical Faculty; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf; Experimental and Clinical Research Center (S.A., F.P., J.B.-S.), a Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin; Charité - Universitätsmedizin Berlin (S.A., F.P., J.B.-S.), corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (S.A., F.P., J.B.-S.), Berlin; Department of Neurology (G.L.), Johanna Etienne Hospital, Neuss; Center for Translational Neuro- and Behavioral Sciences (R.P., J.S., C.K.), University Medicine Essen, University of Duisburg-Essen; Department of Neurology (L.R., L.K.), University Hospital, Münster; Department of Neurology (K.G., A.B.), School of Medicine and Health, Technical University of Munich, Klinikum Rechts der Isar; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H.), University Medical Center Hamburg-Eppendorf; Department of General Pediatrics (M.K.), Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University Düsseldorf; Department of Neurology (K.H., R.G., I.A.), St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (C.O., K.R.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin; Center of Clinical Neuroscience (T.Z.), Department of Neurology, Dresden; Department of Neurology (A.E.)Halle; Department of Neurology (V.R., F.T.N.), Erlangen; Department of Neurology (K.A., R.L.), Regensburg; Department of Neurology (S.A.L., C.W.), University Hospital, Köln; Department of Neurology (S.J., M.K.-K., B.W.), Molecular Neuroimmunology Group, University of Heidelberg; Department of Neurology (S.W.), Gießen; Department of Neurology (M.Seipelt), Marburg; Department of Neurology (Y.Y.), Frankfurt; Department of Neurology (N.R., U.K.Z.), Rostock, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Department of Neurology (M.C.K.), University Hospital, Tübingen; Section of Translational Neuroimmunology (J.W., C.G.), Department of Neurology, Jena University Hospital; Department of Neurology (M.W.H., C.T.), Hannover Medical School; and Department of Neurology (M.Senel), University Hospital, Ulm, Germany.

Article Synopsis
  • Eculizumab (ECU) has shown effectiveness in preventing attacks in patients with aquaporin-4 (AQP4)-IgG seropositive neuromyelitis optica spectrum disorders (NMOSDs) during a retrospective analysis in clinical settings between 2014 and 2022.
  • A total of 52 patients were studied, with 88% being attack-free during treatment, and the annualized attack rate significantly decreased from 1.0 to 0.
  • While common side effects included serious infections, five patients died from various complications, indicating a need for careful monitoring during long-term ECU therapy.
View Article and Find Full Text PDF

is a human-restricted bacteria that is a normal nasopharyngeal resident, yet it can also disseminate, causing invasive meningococcal disease. Meningococci are highly adapted to life in humans, with human-specific virulence factors contributing to bacterial adhesion, nutrient acquisition and immune evasion. While these factors have been explored in isolation, their relative contribution during infection has not been considered due to their absence in small animal models and their expression by different human cell types not readily combined in either or systems.

View Article and Find Full Text PDF

Loss of endothelial integrity and vascular leakage are central features of sepsis pathogenesis; however, no effective therapeutic mechanisms for preserving endothelial integrity are available. Here we show that, compared to dermal microvessels, brain microvessels resist infection by Neisseria meningitidis, a bacterial pathogen that causes sepsis and meningitis. By comparing the transcriptional responses to infection in dermal and brain endothelial cells, we identified angiopoietin-like 4 as a key factor produced by the brain endothelium that preserves blood-brain barrier integrity during bacterial sepsis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!